Skip to main content
generic drug vial

Avenacy debuts generic Integrilin for Injection

Eptifibatide for Injection is indicated for use in acute coronary syndrome and percutaneous coronary intervention.
Levy

Avenacy, a specialty pharmaceutical company that supplies injectable medications, launched Eptifibatide for Injection, a generic for Merck’s Integrilin.

Eptifibatide for Injection is indicated for use in acute coronary syndrome and percutaneous coronary intervention.

Avenacy’s Eptifibatide for Injection is available in a 75 mg/100 ml single-dose vial. In line with the company’s mission to champion patient safety and streamline patient care, the medication will feature highly differentiated packaging and labeling to support accurate medication selection.

[Read more: Global generic drugs market to reach $671.5B by 2030, report finds]

The company is supported by a global network of development and FDA-approved cGMP-certified contract manufacturing partners.

Eptifibatide for Injection had a market value of approximately $8.3 million for the 12 months ending in June 2023, per IQVIA.

Approved indications for the medication include:

  • Acute Coronary Syndrome: Eptifibatide injection is indicated to decrease the rate of a combined endpoint of death or new myocardial infarction in patients with ACS (unstable angina/non-ST-elevation myocardial infarction), including patients who are to be managed medically and those undergoing percutaneous coronary intervention.
  • Percutaneous Coronary Intervention: Eptifibatide injection is indicated to decrease the rate of a combined endpoint of death, new MI, or need for urgent intervention in patients undergoing PCI, including those undergoing intracoronary stenting.

[Read more: Challenges continue, but generics companies see a bright future with] biosimilars] 

X
This ad will auto-close in 10 seconds